The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 retatrutide injection site target that’s showing significant potential in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a significant substantial decrease in body mass and e